07:00 AM EDT, 05/21/2024 (MT Newswires) -- Eli Lilly's ( LLY ) tirzepatide injection was approved for the treatment of adults with type 2 diabetes in China, media reports said Tuesday.

The drug's use for chronic weight management is still under review, Bloomberg reported.

Tirzepatide is the active ingredient in Eli Lilly's ( LLY ) diabetes medicine Mounjaro and weight-loss medicine Zepbound.

The company did not immediately respond to MT Newswires' request for comment.

Price: 784.00, Change: +0.82, Percent Change: +0.10